ClinicalTrials.gg
CompletedNCT01261494Updated Jul 13, 2011

Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

A Phase 2 interventional study of GFT505 80mg and Placebo in Type II Diabetes Mellitus, sponsored by Genfit. Completed at 28 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-07-13.

Sponsored by Genfit · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 235 studies in Diabetes Mellitus, Type 2 with a site in Romania — 10 open to participants now, 18 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Romania.

Enrollment
216th of 228
97 · median 606
Started
2010
with 24 others
Phase 2
41 of 235
1 open now
Registered
114th of 235
by date

Among the 235 studies in Diabetes Mellitus, Type 2 with a site in Romania, this one is the 216th largest by enrollment of the 228 interventional ones that give a count, is one of 25 that started in 2010, is one of 41 in phase 2, and was the 114th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

10 of the 235 studies in Diabetes Mellitus, Type 2 with a site in Romania are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Diabetes Mellitus, Type 2 with a site in Romania, or all of them as a file.
02

Study summary

This study is expected to demonstrate the anti-diabetic efficacy of 3-months treatment with GFT505 (80 mg/d) on Glycosylated Haemoglobin A1c (HbA1C) and fasting plasma glucose.

And to assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 for 12 weeks in patients with type 2 diabetes mellitus.

Read the detailed description

The study period per patient is 16-20 weeks maximum and is conducted as follows :

  • Run-in period: 2 weeks or 6 weeks for patients under fibrate treatment at screening (4 weeks fibrate wash-out + 2 weeks placebo run-in);
  • Treatment period: 12 weeks;
  • Follow-up period: 2 weeks.
03

Conditions studied

  • Type II Diabetes Mellitus

Keywords

  • Diabetes Mellitus, Type 2
  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Cardiovascular Diseases
  • PPARs
  • OGTT
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (defined as >12 months since last menstrual period) or surgical menopause. If hormonal replacement therapy, it should be stable at least for 6 months prior to screening.
  • ≥27 and ≤45 kg/m².
  • Drug-Naive patients with type 2 diabetes mellitus (non insulin dependent diabetes). Patients should not be treated by insulin or other diabetes medication for the last 3 months prior to screening. Patients treated for less than 4 weeks with insulin may be included in the study.
  • ≥ 7.0% and \<9.5%.
  • Antibody glutamate decarboxylase acid (Anti-GAD) negative for patients aged less than 40 years.

Exclusion criteria

Exclusion Criteria:

  • Type I Diabetes Mellitus.
  • Blood Pressure > 160 / 95 mmHg.
  • Lipid-lowering drugs such as fibrates.
  • Fasting Plasma Glucose (FPG) ≥ 240 mg/dL.
  • Triglycerides (TG) > 400 mg/dL.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    GFT505 80mg

    Drug: GFT505 80mg

  • Placebo comparator
    Matching placebo

    Drug: Placebo

Interventions

  • hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast

  • DrugPlacebo

    hard gelatin capsules,oral administration,4 capsules per day before breakfast

06

What researchers measure

Primary outcomes

  1. HbA1c

    To evaluate after 12 weeks of oral administration of double blind treatment the change from baseline in HbA1c level achieved with GFT505 80mg versus placebo. Evaluation will be made during the selection period, prior any drug intake, and 4, 8, 12 weeks after the first treatment intake as well as 2 weeks after the last treatment intake (follow up period).

    Time frame: 12 weeks

Secondary outcomes

  1. Oral Glucose Tolerance Test (OGTT)

    To evaluate the changes from baseline to end of treatment in OGTT parameters. Evaluation will be made prior the first treatment intake and 12 weeks after the first treatment intake.

    Time frame: 12 weeks

  2. Fasting Plasma Glucose

    To evaluate the changes from baseline to end of treatment in fasting plasma Glucose. Evaluation will be made during the selection period, prior any drug intake, and 4, 8, 12 weeks after the first treatment intake as well as 2 weeks after the last treatment intake (follow up period).

    Time frame: 12 weeks

  3. Insulin resistance Index [fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR)]

    To evaluate the changes from baseline to end of treatment in insulin resistance index. Evaluation will be made during the selection period, prior any drug intake, and 4, 8, 12 weeks after the first treatment intake as well as 2 weeks after the last treatment intake (follow up period).

    Time frame: 12 weeks

07

Study locations

28 sites
  • Site n°12
    Banja Luka, 78000, Bosnia and Herzegovina
  • Site n°11
    Sarajevo, 71000, Bosnia and Herzegovina
  • Site n°22
    Riga, LV 1002, Latvia
  • Site n°21
    Riga, LV 1004, Latvia
  • Site n°23
    Valmiera, LV4201, Latvia
  • Site n°33
    Bitola, 7000, Macedonia, The Former Yugoslav Republic of
  • Site n°31
    Skopje, 1000, Macedonia, The Former Yugoslav Republic of
  • Site n°32
    Skopje, 1000, Macedonia, The Former Yugoslav Republic of
  • Site n°41
    Balti, 3112, Moldova, Republic of
  • Site n°42
    Chisinau, 2025, Moldova, Republic of
  • Site n°43
    Chisinau, 2068, Moldova, Republic of
  • Site n°72
    Oradea, Bihor County 410167, Romania
  • Site n°66
    Buzau, Buzau County 120203, Romania
  • Site n°64
    Cluj Napoca, Cluj County 400006, Romania
  • Site n°65
    Baia Mare, Maramures County 430123, Romania
  • Site n°63
    Targu Mures, Mures County 540098, Romania
  • Site n°62
    Targu Mures, Mures County 540142, Romania
  • Site n°71
    Ploiesti, Prahova County 100163, Romania
  • Site n°70
    Ploiesti, Prahova County 100342, Romania
  • Site n°61
    Sibiu, Sibiu County 550245, Romania
  • Site n°67
    Bucharest, 020045, Romania
  • Site n°69
    Bucharest, 020045, Romania
  • Site n°68
    Bucharest, 020475, Romania
  • Site n°52
    Belgrade, 11000, Serbia
  • Site n°53
    Belgrade, 11000, Serbia
  • Site n°56
    Belgrade, 11000, Serbia
  • Site n°54
    Kragujevac, 34000, Serbia
  • Site n°51
    Nis, 18000, Serbia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2010
First posted
Dec 16, 2010
Start
Dec 2010
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Last update
Jul 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01261494
Lead sponsor
Genfit
First posted
Dec 16, 2010
Start date
Dec 2010
Primary completion
Jun 2011
Completion
Jun 2011
Last update
Jul 13, 2011

Study contacts

Rémy HANF, Development Director
study director · Genfit, France
Bertrand CARIOU, Pr.
study chair · University Hospital of Nantes, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion